S10 E6: Modern Antibody-drug conjugates and New CINV Challenges
Published Date:
With podcast host, Ginger Blackmon, and featuring Kirollos Hanna, PharmD, BCPS, BCOP.
In this episode, we welcome Kirollos Hanna, PharmD, BCPS, BCOP, a recognized leader in oncology pharmacy practice and research. Dr. Hanna shares insights into the evolving landscape of antibody-drug conjugates (ADCs) and the unique challenges they present in managing chemotherapy-induced nausea and vomiting (CINV).
As ADC use expands, oncology teams are observing new and sometimes underrecognized patterns of nausea and vomiting, particularly with HER2-directed therapies and delayed-phase symptoms that extend beyond the traditional monitoring window. This discussion highlights how these patterns differ from conventional chemotherapy and what that means for clinical practice.
Dr. Hanna also reviews emerging pharmacokinetic data and clinical trial evidence supporting the use of NK1 receptor antagonist–based antiemetic strategies. The conversation emphasizes practical, actionable approaches for optimizing supportive care, improving patient quality of life, and ensuring proactive symptom management within the medically integrated oncology team.
Learning Objectives:
- Describe emerging patterns of chemotherapy-induced nausea and vomiting (CINV) associated with antibody–drug conjugates (ADCs), with emphasis on HER2-directed ADCs and delayed-phase nausea beyond day 5
- Discuss pharmacokinetic and clinical trial evidence on NK1 receptor antagonist–based antiemetic strategies when optimizing CINV prevention for patients receiving ADC therapy.
This activity provides 0.5 hours of CE credit for pharmacists and pharmacy technicians. Click here to claim CE credit.
Guest: Kirollos Hanna, PharmD, BCPS, BCOP, Director of Pharmacy, Minnesota Oncology, Assistant Professor of Pharmacy, Mayo Clinic College of Medicine, Associate Editor, Journal of the Advanced Practitioner in Oncology (JADPRO)
Disclosures: Speaker: BeOne, BMS, Exelixis, Pfizer Consulting Fees: BeOne, BMS, Exelixis, Pfizer, Astrazeneca
Recent Episodes
S10 E4: Preventing Blood Clots in Cancer Care
This episode spotlights the often-overlooked impact of blood clots in cancer care, with Leslie Lake of the National Blood Clot Alliance sharing insights on awareness, education, and prevention.
March 10, 2026
S10 E3: No Room for Shortages: Protecting Patients Through Advocacy + Action
Laura Bray, MBA (Angels for Change) joins for a conversation on oncology drug shortages—her personal story, the current landscape, and practical steps pharmacists and care teams can take to support patients and strengthen access.
March 4, 2026
S10 E2: Bringing Care Closer to Home: Advancing Rural Oncology
Bhavana (Tina) Bhatnagar shares her move from academic centers to rural West Virginia and what it takes to expand access to high-quality cancer care for underserved communities, from overcoming transportation and financial barriers to building community-based clinical trials and bringing innovations like CAR T closer to home.
February 25, 2026